Appointment of Internal Auditor for Financial Year 2025-26 Appointment of Secretarial Auditor Apppintment of cost auditor for the Financial Year 2025-26 and others
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical reported Q1 FY26 results showing revenue growth but sharply widened losses. Revenue from operations rose to Rs 1,513.47 lakhs from Rs 1,262.08 lakhs a year ago, a roughly 20% YoY increase. However, net loss ballooned to Rs (610.61) lakhs versus Rs (136.33) lakhs in Q1 FY25, with loss before tax deepening to Rs (814.80) lakhs from Rs (281.70) lakhs. EPS deteriorated to Rs (1.65) from Rs (0.39). Total expenses grew to Rs 2,343.99 lakhs, driven by higher raw material and manufacturing costs. Exceptional items of Rs 1.18 lakhs relate to provident fund damages. The board appointed new internal, secretarial, and cost auditors for FY26 and replaced the Company Secretary Dolly Mandhan with Kumkum Bajaj. Notes flagged ongoing gaps in MSME creditor identification and aging schedule preparation, indicating weak internal controls.
Despite topline growth, losses widened nearly 4.5x YoY as costs rose faster than revenue, signalling serious margin pressure and continued cash burn for shareholders. The auditor and Company Secretary reshuffle are routine governance items, but the persistence and depth of losses remain the key concern for the stock.